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ABSTRACT
CYLD, an ubiquitin hydrolase, has an expanding repertoire of regulatory roles in 
cell signalling and is dysregulated in a number of cancers. To dissect CYLD function we 
used a proteomics approach to identify CYLD interacting proteins and identified MIB2, 
an ubiquitin ligase enzyme involved in Notch signalling, as a protein which interacts 
with CYLD. Coexpression of CYLD and MIB2 resulted in stabilisation of MIB2 protein 
levels and was associated with reduced levels of JAG2, a ligand implicated in Notch 
signalling. Conversely, gene silencing of CYLD using siRNA, resulted in increased JAG2 
expression and upregulation of Notch signalling. We investigated Notch pathway 
activity in skin tumours from patients with germline mutations in CYLD and found that 
JAG2 protein levels and Notch target genes were upregulated. In particular, RUNX1 
was overexpressed in CYLD defective tumour cells. Finally, primary cell cultures of 
CYLD defective tumours demonstrated reduced viability when exposed to γ-secretase 
inhibitors that pharmacologically target Notch signalling. Taken together these data 
indicate an oncogenic dependency on Notch signalling and suggest potential novel 
therapeutic approaches for patients with CYLD defective tumours.
INTRODUCTION
Ubiquitylation of proteins is a key post-translational 
modification and plays a role in targeting proteins 
for degradation via the proteasome as well as having 
roles in membrane trafficking, DNA repair, protein 
kinase activation and chromatin modification [1–3]. 
The covalent attachment of the 76 amino acid ubiquitin 
molecule to a protein is achieved via a cascade mediated 
by three enzyme classes: E1 (ubiquitin activating 
enzymes), E2 (ubiquitin conjugating enzymes) and E3 
(ubiquitin ligases). Ubiquitylation often takes the form of 
polymeric ubiquitination, forming ubiquitin chains that 
are progressively linked through lysine-48 or lysine-63 
residues. There are also five other lysine residues present in 
ubiquitin (K6, K11, K27, K29, K33) that are also believed 
to take part in atypical chain elongation [4]. Furthermore, 
the type of ubiquitin linkage formed is thought to 
determine the subsequent signal (e.g. degradation, DNA 
repair, receptor endocytosis). Finally, deubiquitylation of 
proteins performed by a set of deubiquitylating enzymes 
(DUBs) is considered as a crucial mechanism for cell 
regulation [5, 6]. DUBs and ubiquitin ligase enzymes can 
act as molecular partners, allowing for tight regulation of a 
variety of cellular process dependent on ubiquitylation [5].
The tumour repressor protein CYLD, a DUB, has 
previously been shown to suppress potentially oncogenic 
NF-κB signalling [7–9]. Loss of functional CYLD causes 
a disease known as Brooke-Spiegler syndrome (BSS). 
BSS is characterised by skin tumours that originate from 
hair follicles and predominantly affects the scalp and 
face. Specifically, BSS is caused by heritable mutations 
in CYLD that cause protein truncation and disruption of 
its ubiquitin-specific protease (USP) domain [10, 11]. 
CYLD negatively regulates NF-κB activation by removing 
lysine-63 linked ubiquitin chains from TRAF2/6, NEMO 
and BCL3, and loss of CYLD leads to hyper-activation 
of NF-κB signalling and an increased susceptibility to 
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cutaneous tumour formation in mouse knockout models 
[7, 9, 12]. RNA interference based silencing (RNAi) of 
CYLD also results in activation of JNK signalling and 
Cyld deficient mice develop severe colonic inflammation, 
colitis-associated tumours, and hepatocellular carcinoma 
[13–15]. CYLD has also been shown to play a role in 
regulating other oncogenic signalling pathways that are 
relevant in skin tumours, including Wnt [16] and TGF-β 
signalling [17].
In haematological malignancies such as T-cell acute 
lymphoblastic leukaemia (T-ALL), Notch signalling 
regulates CYLD expression. Aberrant Notch signalling 
has been shown to sustain NF-κB signalling via Hes1 
mediated repression of CYLD [18]. Synergistic cross-
talk between Notch and NF-κB signalling has also been 
demonstrated in murine models of pancreatic cancer, 
where TNF-alpha has been shown to induce Notch target 
gene expression [19]. Notch signalling in development, 
dissected in Drosophila studies, is dependent on direct 
cellular interactions with neighbouring cells [20]. This 
interaction, central to processes in development such 
as restriction of organ size, is thought to be altered in a 
range of cancers, where it facilitates processes such as 
aberrant angiogenesis and stromal oncogenic dependency. 
Notch signalling has been shown to play a role (reviewed 
by Ranganathan et al. [21]) in an increasing variety of 
cancer types. A number of therapeutic approaches to 
blocking Notch signalling are being developed, including 
γ-secretase inhibitors.
In the minimal model of two cells communicating 
via Notch signalling, the “message-sending” cell relies 
upon ubiquitylation of the intracellular domain of the 
Delta/Serrate/LAG-2 (DSL) family to facilitate the 
formation of a signalling focus (microdomain) that 
allows interaction with the “message-receiving” cell. E3 
ligases and ubiquitin hydrolases can also modulate Notch 
signalling by regulating levels of expression of DSL 
ligands by influencing their degradation [22].
Mind Bomb homologue 2 (MIB2)/skeletrophin is 
an E3 ligase that targets the intracellular region of the 
Notch family ligand, Jagged-2 (JAG2) [23]. Together 
with Neur and MIB, MIB2 shares a structural E3 “really 
interesting new gene” (RING) ligase domain that catalyses 
the addition of single or short chains of ubiquitin to the 
lysine residues that lie in the intracellular domains of DSL 
ligands such as JAG2. Aberrant JAG2 activity has been 
shown to be pathogenic in cancers such as myeloma [23], 
and hence dissection of its regulation might be of 
therapeutic importance.
Here, we report a novel interaction between 
CYLD and MIB2 and explore the effect of these 
proteins on Notch signalling. The presence of aberrant 
Notch signalling in skin tumours from patients 
with BSS further supports the hypothesis that the 
CYLD/MIB2 interaction might play a pathogenic role 
in human cancer.
RESULTS
CYLD interacts with MIB2
To identify novel functions of CYLD, we performed 
a proteomic analysis of CYLD interacting proteins 
[24, 25]. Briefly, this involved the co-purification of an 
exogenously expressed CYLD ‘bait’ protein in complex 
with any interacting ‘target’ protein(s), followed by SDS-
PAGE based protein separation, protein extraction and 
subsequent identification of potential interacting proteins 
using mass spectrometry (see Materials and Methods).
The ubiquitin hydrolase domain of CYLD 
(CYLDUSP- amino acid residues 583-956), which was 
used as a ‘bait’ protein (To detect interacting proteins 
with the catalytic portion of CYLD), was expressed as 
a fusion protein with glutathione-S-transferase (GST) 
following transfection into HEK-293T cells. TNF-alpha 
was added to the media to stimulate NF-κB signalling. 
CYLD-associated proteins from cells expressing CYLDUSP 
were isolated using a GST-based precipitation assay. 
Whole cell lysates generated from transfected cells were 
incubated with glutathione sepharose and the resin bound 
complex(es) copiously washed with buffer to remove 
non-specifically binding contaminants. To control for 
non-specific binding effects mediated by the GST tag, this 
analysis was also carried out in cells expressing the GST 
tag alone. GST-CYLDUSP and possible binding partners 
were then electrophoresed on PAGE gels and visualised 
by silver staining (Figure 1A). Prominent bands associated 
with the expression of GST-CYLDUSP but not GST alone 
were then excised and subject to tryptic digestion. Matrix 
Assisted Laser Desorption-TOF-TOF mass spectrometry 
was then used to identify these digested products and 
bioinformatic identification using fragment ion search was 
carried out using the ProFound search engine (Rockefeller 
University) [26].
Amongst the bands analysed by mass spectrometry, 
MIB2 was identified with reasonable probability as a 
CYLD interacting protein (P = 81%) and 12 different 
MIB2 peptides, representing 13% of the total MIB2 
amino acid sequence, were identified (Supplementary 
Table 1). MIB2 is an E3 ubiquitin ligase associated 
with the Notch pathway and its interaction with an 
ubiquitin hydrolase, CYLD, raised the possibility that 
this interaction may highlight a novel mechanism of 
regulating Notch signalling. Therefore, the CYLD/MIB2 
interaction was investigated in more detail. The interaction 
of CYLD-MIB2 was seen both in unstimulated and TNF-
alpha stimulated cells, and subsequent experiments were 
performed without TNF-alpha stimulation (Supplementary 
Figure 1). The interaction between endogenous CYLD and 
MIB2 was validated by co-immunoprecipitation of CYLD 
with MIB2 (Figure 1B). This experiment was performed in 
the presence of the proteasome inhibitor MG-132, which 
reduced the rate of degradation of MIB2-Ubiqitin species, 
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allowing this interaction to be more easily detected. The 
potential for a functional interaction between CYLD and 
MIB2 was investigated further.
Characterisation of the CYLD/MIB2 interaction
MIB2 is an E3 ligase, known to ubiquitylate itself 
and the intracellular region of JAG2, which is a single 
pass transmembrane protein [23]. To further dissect the 
nature of the CYLD/MIB2 interaction, we performed 
ubiquitylation assays, which allowed us to quantify the 
expression of both proteins and respective ubiquitylated 
species when catalytically active and inactive CYLD and 
MIB2 were expressed. These assays were performed by 
transiently co-transfecting HEK-293T cells with cDNA 
constructs containing the open reading frame of either 
CYLD, MIB2 or both in combination, together with a 
construct expressing polyhistidine tagged ubiquitin (His
6
-
ubiquitin). The expression of His
6
-ubiquitin allowed us to 
analyse ubiquitin conjugated proteins following capture 
by nickel affinity chromatography under denaturing 
conditions. First, co-transfection of haemagglutinin 
epitope tagged-MIB2 (HA-MIB2) [27], CYLD (untagged) 
and His
6
-ubiquitin expression constructs clearly drove the 
ubiquitylation of CYLD compared to cells transfected 
with CYLD and His
6
-ubiquitin (Figure 2A panel (i), 
compare lanes 1 and 2), suggesting that MIB2 may 
ubiquitylate CYLD. To test whether loss of MIB2 E3 
ligase activity mediated these effects, the C-terminus of 
the HA-MIB2 construct was mutated so that it expressed 
MIB2 without the catalytic RING domains (HA-MIB2-
ΔRING). Co-transfection of CYLD/HA-MIB2-ΔRING/
His
6
-ubiquitin prevented auto-ubiquitylation of MIB2 
(Figure 2A, panel (iii), compare lanes 2 and 3) and did 
not result in ubiquitylation of CYLD (Figure 2A panel (i), 
compare lanes 2 and 3). The latter observation suggested 
that MIB2 catalytic activity could be responsible for the 
ubiquitylation of CYLD. Furthermore, overexpression 
Figure 1: MIB2 interacts with CYLD. (A) MIB2 interacts with CYLD in GST pull down assays. The ubiquitin hydrolase catalytic 
domain of CYLD (CYLDUSP) was expressed as a fusion protein with glutathione-S-transferase (GST) in HEK-293T cells and CYLD-
associated proteins were isolated from whole cell lysates using a GST pull down assay. MIB2 co-purified with recombinant GST-CYLD 
ubiquitin specific protease domain (GST-CYLDUSP) and was identified by subjecting excised bands to tryptic digest followed by matrix assisted 
laser desorption and tandem mass spectrophotometry (also see Supplementary Table 1). (B) Endogenous immunoprecipitation of MIB2 by 
CYLD. Control rat IgG or rat anti-CYLD monoclonal antibody (2 μg) were incubated with HEK-293T lysates. After immunoprecipitation, 
the eluted proteins were analysed by western blot using a rabbit anti-MIB2 polyclonal antibody. MIB2 is immunoprecipitated by CYLD 
and not IgG control (panel i). Tubulin expression was used as a loading control (panel ii).
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Table 1: Notch target genes are upregulated in CYLD defective tumours. Gene expression data from 
32 cylindroma tumours and 10 control perilesional skin samples were pooled into tumour and control 
groups. Differentially expressed genes with a threshold of p < 0.05 were included and the fold changes 
(FC) are indicate for the respective transcripts.
Gene FC ILMN Probe ID Description
DTX3 3.13 ILMN_1658677 Deltex homolog 3 (Drosophila)
HEY1 2.73 ILMN_1788203 Hairy/enhancer-of-split related with YRPW motif 1
JAG2 2.50 ILMN_2399523 Jagged 2
HEY1 2.43 ILMN_2407308 Hairy/enhancer-of-split related with YRPW motif 1
DLL3 2.40 ILMN_1736096 Delta-like 3 (Drosophila)
RUNX1 2.33 ILMN_1801504 Runt-related transcription factor 1
HOXA9 2.19 ILMN_1739582 Homeobox A9
TCF3 2.09 ILMN_1664434
Transcription factor 3 (E2A immunoglobulin enhancer binding factors 
E12/E47)
NFKB2 1.91 ILMN_1799062
Nuclear factor of kappa light polypeptide gene enhancer in B-cells 2  
(p49/p100)
CD3G 1.88 ILMN_1717197 CD3g molecule, gamma (CD3-TCR complex)
JAG2 1.87 ILMN_1764729 Jagged 2
LEF1 1.80 ILMN_2213136 Lymphoid enhancer-binding factor 1
NOTCH1 1.67 ILMN_1729161 Notch homolog 1, translocation-associated (Drosophila)
HAT1 1.65 ILMN_1693905 Histone acetyltransferase type B catalytic subunit
PSEN1 1.56 ILMN_1809193 Presenilin 1
RUNX1 1.54 ILMN_1669335 Runt-related transcription factor 1
HESX1 1.38 ILMN_1742929 HESX homeobox 1
FURIN 0.68 ILMN_1790228 Furin (paired basic amino acid cleaving enzyme)
PSEN2 0.61 ILMN_1714417 Presenilin 2 (Alzheimer disease 4)
PSEN2 0.49 ILMN_2404512 Presenilin 2 (Alzheimer disease 4)
DLL1 0.45 ILMN_1743373 Delta-like 1 (Drosophila)
CEBPA 0.44 ILMN_1715715 CCAAT/enhancer binding protein (C/EBP), alpha
NOTCH3 0.43 ILMN_1658926 Notch homolog 3 (Drosophila)
HES2 0.43 ILMN_2094266 Hairy and enhancer of split 2 (Drosophila)
GATA3 0.34 ILMN_2406656 GATA binding protein 3
ETS2 0.32 ILMN_1720158 V-ets erythroblastosis virus E26 oncogene homolog 2 (avian)
of MIB2 but not MIB2-ΔRING appeared to decrease 
endogenous levels of its downstream target, JAG2 
(Figure 2A, panel (iv)), presumably by promoting its 
endocytosis and degradation, which is mechanistically 
consistent with previous observations [23]. Taken 
together, these observations suggested that MIB2 
ubiquitylates CYLD leading to CYLD destabilisation 
and degradation, and that CYLD might be involved in 
regulation of JAG2, and ultimately Notch signalling, via 
its interaction with MIB2.
As we demonstrated that MIB2 can ubiquitylate 
itself as well as CYLD, we postulated that CYLD, as an 
ubiquitin hydrolase, might deubiquitylate MIB2, hence 
providing a potential mechanism of mutual regulation. 
To test this hypothesis we assessed the effect of CYLD 
catalytic activity upon MIB2 ubiquitylation levels. Cell 
lysates prepared in denaturing buffer were purified by 
nickel chromatography and analysed by western blotting. 
This demonstrated that in the absence of exogenous 
CYLD expression, overexpression of HA-MIB2/His
6
-
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Figure 2: Characterisation of the ubiquitylation status and protein levels of CYLD and MIB2. (A) MIB2 ubiquitylates 
CYLD, resulting in its degradation and a reduction in levels of Notch ligand JAG2. HA-MIB2, CYLD (untagged) and His
6
-ubiquitin 
constructs were co transfected in HEK-293T cells and drove the ubiquitylation of CYLD compared to cells transfected with CYLD/
His
6
-ubiquitin alone (panel (i), compare lanes 1 and 2). Co-transfection of CYLD/HA-MIB2-ΔRING/His
6
-ubiquitin prevented auto-
ubiquitylation of MIB2 (panel (iii), compare lanes 2 and 3) and did not result in ubiquitylation of CYLD (panel (i), compare lanes 2 
and 3). Overexpression of MIB2 but not MIB2-ΔRING appeared to decrease endogenous levels of its downstream target, JAG2 (panel 
(iv)). Tubulin was used as a loading control (panel (v)). (B) CYLD expression is associated with increased ubiquitylated MIB2 protein 
and reduced JAG2 protein, independent of its ubiquitin hydrolase activity. Lysates from transfected cells prepared in denaturing buffer 
were analysed by western blot and purified by nickel chromatography and showed that in the absence of exogenous CYLD expression, 
overexpression of HA-MIB2/His
6
-ubiquitin predominantly resulted in high order molecular weight (MW) products at around 150 kDa 
(panel (i), lane 2) and decreased MIB2 in the whole cell lysate (panel (ii), lane 2 compared to lane 4 and 5). In the presence of exogenous 
CYLD expression, a larger proportion of lower MW ubiquitylated MIB2 products were observed (panel (i) compare lane 2 vs. lane 4). 
In order to determine whether this was dependent on CYLD deubiquitylase activity, HA-MIB2/His
6
-ubiquitin was co-expressed with a 
catalytically inactive CYLD (CYLD-C601A, with no apparent difference in poly-ubiquitylated MIB2 levels versus co-expression with 
wild type CYLD seen (panel (i), compare lane 4, 5 and MIB2 levels in whole cell lysate, panel (ii), lanes 2, 4 and 5). Tubulin was used as 
a loading control (panel (v)).
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ubiquitin predominantly resulted in high order molecular 
weight (MW) MIB2 ubiquitylated products at around 
150 kDa (Figure 2B panel (i), lane 2) and decreased 
MIB2 expression in the whole cell lysate (Figure 2B, 
panel (ii), lane 2 compared to lane 4 and 5). However, 
in the presence of exogenous CYLD expression, a larger 
proportion of lower MW ubiquitylated MIB2 products 
were observed (Figure 2B panel (i) compare lane 2 vs. 
lane 4). This suggests that CYLD may play a role in 
MIB2 regulation and subsequent Notch signalling, as 
in this case we appear to observe that overexpression 
of CYLD causes a stoichiometric imbalance of high- 
and low-molecular weight MIB2-(Ubiquitin)n species. 
Inefficient MIB2 processing, which is normally carried 
out via proteasomal degradation of higher molecular 
weight MIB2-(Ubiquitin)n species [28], could then lead 
to dysregulation of JAG2 levels and, consequently, the 
downstream Notch signal.
In order to determine whether this was dependent on 
CYLD deubiquitylase activity, HA-MIB2/His
6
-ubiquitin 
was co-expressed with a catalytically inactive CYLD 
mutant cDNA (CYLD-C601A, [9]). However we observed 
no apparent difference in poly-ubiquitylated MIB2 levels 
in CYLD-C601A expressing cells compared to wild-type 
CYLD expressing cells (Figure 2B, panel (i), compare 
lane 4, 5 and MIB2 levels in whole cell lysate, panel (ii), 
lanes 2, 4 and 5).
Taken together these results suggested that CYLD 
interacts with and is ubiquitylated by MIB2. However 
likely MIB2 is not a deubiquitylation target of CYLD, but 
rather is stabilised by CYLD in a non-catalytic dependent 
manner. The MIB2 target, JAG2, also did not appear to 
be a deubiquitylation target of CYLD (data not shown). 
The observed stabilisation of MIB2 by CYLD appeared 
to effect downstream degradation of endogenous JAG2. 
(Figure 2B, panel (iv), lanes 4 and 5).
CYLD depletion activates Notch signalling
We assessed the potential role of the CYLD/MIB2 
interaction with respect to Notch signalling. CYLD 
depletion using siRNA is known to activate NF-κB 
signalling [9], and we therefore investigated the effect 
this had on the Notch pathway. CYLD siRNAs were 
transfected into cells that had been stably transduced with 
a lentiviral luciferase reporter under the control of the 
RBP-JK transcriptional response element, which served 
as a readout of Notch signalling. Seventy-two hours post-
transfection, the cell lysates were assayed for RBP-JK 
related luciferase activity (Figure 3A). Notch activation 
in CYLD siRNA transfected cells was normalised to 
cells transfected with non-silencing siRNA. This analysis 
showed that Notch activity significantly increased 
( p < 0.01 - unpaired t-test) in response to gene silencing 
of CYLD; efficient CYLD silencing by the siRNA was 
confirmed by western blot analysis (Figure 3B). Increased 
JAG2 expression was also demonstrated in 293 cells 
with CYLD silencing (Figure 3C). To determine if this 
finding was relevant in a human model, we assessed JAG2 
expression in CYLD defective tumour lysates, obtained 
from patients with germline CYLD mutations. These 
consisted of 5 cylindromas and 1 spiradenoma, obtained 
from 4 patients. Normal skin exhibited undetectable levels 
of JAG2 compared to 5 cylindromas and one spiradenoma, 
even when enhanced amounts of normal skin protein were 
assessed in western blots (Figure 3D).
Notch target genes are dysregulated in CYLD 
defective tumours
Given the increase in luciferase activity indicative of 
Notch activity in cells transfected with CYLD siRNA, we 
explored the consequences of CYLD inactivation in skin 
tumours from patients with germline mutations in CYLD. 
This model was used to determine if features associated 
with increased Notch signalling such as the expression of 
Notch target genes were demonstrated in a human CYLD 
defective model, as suggested by the luciferase assay. We 
assessed the expression of 98 Notch related transcripts, 
including Notch target genes and Notch signalling 
pathway components [29], in a dataset of gene expression 
profiles of CYLD defective tumours [30]. Genes that 
were differentially expressed in the pooled signature of 32 
CYLD defective tumours compared to 10 controls with 
a threshold for statistical significance of p < 0.05 after 
correction for multiple hypothesis testing were included 
(n = 26). The fold changes of these genes are detailed 
in Table 1. To visualise the expression of each of these 
genes at an individual sample level, normalised signal 
values were plotted on a heatmap following logarithmic 
transformation (Figure 4). Clustering of this data by 
Euclidean distance clearly differentiated the tumours from 
the control tissue. Six tumours (Tumour numbers: 1, 10, 
11, 15, 25, 30), of which four were trichoepitheliomas 
in the study set clustered distinctly from the majority 
of cylindroma and spiradenomas (n = 28). A number of 
Notch target genes were consistently overexpressed in 
CYLD defective tumours, including LEF1, HEY1 and 
NOTCH1. The increased expression of JAG2 in CYLD 
defective tumours in particular supported our in vitro 
findings that CYLD-MIB2 regulation of Notch signalling 
influences expression levels of the ligand JAG2.
To validate these findings, we performed 
quantitative PCR on RNA isolated from a subset of 
CYLD defective tumours used in the microarray study. 
Expression of HEY1 transcript was assessed in 15 CYLD 
defective tumours (Supplementary Figure 2). RNA was 
extracted from microdissected, snap-frozen tumour 
tissue and subject to quantitative PCR using probes for 
HEY1. Beta-actin expression was also assessed and used 
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to normalise expression levels. Differential expression 
was calculated using the 2 (-ΔΔCt) formula as amplification 
efficiencies were similar. This demonstrated upregulation 
of the Notch target gene HEY1 in all specimens assayed, 
consistent with the findings from the microarray data.
Immunohistochemical assessment of the 
expression of Notch target genes in CYLD 
defective tumours
To determine whether the observations described 
above seen in mRNA were reflected in changes in protein 
expression, we assessed protein expression of selected 
upregulated Notch target genes in CYLD defective 
tumours, and adjacent normal epidermis was used as 
a control. Strong nuclear staining of protein from both 
Notch target genes LEF1 and RUNX1 were observed 
in cylindromas, spiradenomas and trichoepitheliomas 
(Figure 5a). Assessment of protein expression by 
measurement of immunostaining intensity using Image J 
software showed this effect to be statistically significant 
when compared to adjacent normal epidermis (Figure 5b - 
LEF 1 p = 0.013; RUNX1 p = 0.001). We also examined 
expression of HES1, a canonical Notch target gene not 
highlighted by the microarray data. Nuclear HES1 was 
seen to be increased in CYLD defective tumours, but 
the difference from control epidermis was smaller than 
for LEF1 and RUNX1 (p = 0.027). Taken together, these 
data validate the microarray data at the protein level and 
highlight CYLD defective tumours as a model tumour 
type characterised by aberrant Notch signalling.
Primary cultures of CYLD defective tumours 
are sensitive to γ-secretase inhibitors
γ-Secretase inhibitors suppress Notch signalling by 
impairing cleavage and release of the intracellular domain 
of Notch protein (NICD). A reduction in free NICD results 
Figure 3: CYLD ablation results in increased Notch signalling. (A) HEK-293T cells stably expressing a RBP-JΚ response 
element coupled to a firefly luciferase were used as a readout for active Notch signalling. Notch signalling was significantly increased 
following CYLD knockdown with siRNA targeting CYLD (unpaired t-test). (B) CYLD protein expression reduction following siRNA 
targeting was demonstrated by probing lysates from transfected cells with anti-CYLD antibody (C) CYLD protein expression reduction is 
associated with increased JAG2 expression, and (D) increased JAG2 expression is seen in the majority of CYLD defective tumour lysates 
obtained from patients with germline mutations in CYLD.
Oncotarget12133www.impactjournals.com/oncotarget
Figure 4: Notch target genes and members of the Notch signalling pathway are overexpressed in CYLD defective 
tumours. A heatmap plot illustrating the expression levels of Notch signalling pathway and target genes in 32 CYLD defective tumours 
and 10 controls. Notch target genes and signalling pathway members that were differentially expressed with a p value of <0.05 across 
an average of 32 tumours compared to an average of 10 controls (tumours and controls are indicated at the bottom of the heatmap) were 
included, and transcript expression levels at a single sample level are illustrated in the heatmap. Overexpressed transcripts are shown in red 
and transcripts that are underexpressed are shown in blue, with gene names indicated on the right hand side of the figure. Where data from 
multiple transcripts for a single gene were available, these are indicated with a numerical suffix (n = 4). Clustering by similarity is shown 
as determined by Euclidean distance.
in its reduced nuclear translocation and binding to the 
RBP-JK complex, with a consequent reduction in 
transcription of Notch target genes[31]. To determine 
if CYLD defective tumours exhibited an oncogenic 
dependency on Notch signalling, primary cells derived 
from these tumours were cultured on 3D scaffolds as 
previously described [30]. Briefly, these are primary cells 
derived from explant culture of CYLD defective tumours 
removed from patients with known germline mutations in 
CYLD. These cells were obtained immediately following 
tumour-burden reductive surgery. Cells were grown on 
3D tissue culture scaffolds and allowed to mature over 28 
days, before they were cultured in varying concentrations 
of γ-secretase inhibitors. These CYLD defective primary 
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Figure 5: Expression of Notch target genes in CYLD defective tumours. (A) Tissue microarrays of cylindromas and 
spiradenomas and perilesional control skin were probed with anti-RUNX1, anti-LEF1 and anti–HES1 antibody and protein expression 
was visualized with a horseradish peroxidase/ 3,3’-Diaminobenzidine (DAB) system, with haematoxylin used as a nuclear counterstain. 
Nuclear staining of LEF1, RUNX1 and HES1 was seen in CYLD defective tumours. Scale bars indicate 100μm. (B) Notch target proteins 
are increased in CYLD defective tumours when compared to perilesional control skin. Photomicrographs of tumour sections and control 
tissue were subject to quantitation of DAB staining as a readout of protein expression. This demonstrated an increase in expression of 
LEF1 ( p = 0.001), RUNX1 ( p = 0.013) and HES1 ( p = 0.027) in CYLD defective tumours when compared to control tissue. All p-values 
indicated were derived using a t-test. Error bars indicate standard error of the mean
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cultures demonstrated sensitivity to γ-secretase inhibition at 
micromolar concentrations (Figure 6). A similar sensitivity 
was not seen in controls of a keratinocyte cell line (HaCAT) 
grown in identical conditions.
DISCUSSION
Here we report a novel interaction between an 
ubiquitin hydrolase, CYLD, and an ubiquitin ligase, MIB2, 
and its consequences on Notch signalling. Ubiquitylation 
serves as a regulatory process in multiple cell signalling 
cascades, which underscores the significance of a 
novel ubiquitin hydrolase-ubiquitin ligase interaction. 
Deubiquitylases and E3 ligases frequently interact [32]. 
CYLD and ITCH (an ubiquitin ligase) are one such pair, 
interacting to regulate inflammation by modifying the 
ubiquitylation status of TAK1 and hence modulating 
NF-κB signalling [33]. The effect of such an interaction 
may regulate E3 ligase autoubiquitylation [34], confer 
specificity between the DUB and substrate [35] or allow 
the E3 ligase to regulate its target as well as its DUB 
simultaneously [36].
MIB2, has been shown to modulate Notch 
signalling [23]. MIB2 binds to the intracellular domain 
of JAG2, but not other Notch ligands such as JAG1 or 
DLL. Ubiquitination of intracellular JAG2 is thought 
to increase the effectiveness of Notch signalling, and is 
associated with increased expression of Notch target 
gene HES1. Mechanistically, this is thought to be due 
to MIB2 mediated endocytosis of JAG2 in the message 
sending cell which is important for Notch ligand activation 
in the message receiving cell [37]. Our data suggests 
that the CYLD/MIB2 interaction may attenuate Notch 
signalling by reducing levels of JAG2 (Figure 7). In 
our overexpression studies, reduction of JAG2 appears 
to be independent of the catalytic activity of CYLD, 
and may be due to stabilisation of MIB2. Given the 
specificity of CYLD for K63-ubiquitin linked chains [38], 
our data would suggest that (1) auto-ubiquitylation of 
MIB2 is most likely a K48-ubiquitin event leading to its 
proteasomal degradation (in agreement with [23]); (2) the 
CYLD-MIB2 protein-protein interaction physically 
prevents efficient auto-ubiquitylation and degradation of 
MIB2; and (3) MIB2 regulates this process by targeting 
CYLD for degradation.
The CYLD defective tumours described here 
provide a human skin tumour model to explore the effects 
of truncating CYLD mutations on Notch signalling in a 
disease-relevant cellular context. These tumours have 
been characterised previously and frequently demonstrate 
loss of heterozygosity at the locus of CYLD [30]. We have 
previously shown that JAG2 is upregulated in CYLD 
defective tumour tissue, particularly in “Wnt active” 
tumours [39]. Here, we demonstrate that recognised Notch 
target genes are upregulated in this model, including 
RUNX1, LEF1, and HES1. Whilst some Notch genes were 
consistently upregulated, others varied between tumours. 
At the protein level, RUNX1 expression in cylindroma 
has recently been highlighted by Scheike et al. [20], and 
our data extends the expression of RUNX1 to include 
spiradenoma and trichoepithelioma, suggesting that this 
is a feature consistent across CYLD defective tumours. 
RUNX1 expression has been shown to be oncogenic in 
murine models [40], exerted via downstream effects on 
Figure  6: Primary  cultures  of CYLD defective  tumours  are  sensitive  to  γ-secretase  inhibitors. Primary cells (CPCC) 
derived from fresh tumour tissue obtained following surgical procedures on CYLD mutation carriers or a keratinocyte cell line (HACAT) 
were cultured on 3D tissue culture scaffolds. After 28 days, scaffolds were grown in the presence of two different γ-secretase inhibitors 
(YO-0107 and LY 450139) for 12 days in triplicate and cell viability was assessed using an ATP dependent luminescent assay (Cell-Titre 
Glo – Promega UK). This was repeated using at least three different tumours, from different body sites in three patients. Data displayed 
represents the mean of 4 biological replicates of CPCC, with 3 technical replicates each. Cylindroma cells demonstrated differential 
sensitivity to inhibition with γ-secretase inhibitors at low micromolar concentrations of YO-0107 and LY 450139. Error bars indicate 
standard error of the mean. p < 0.05 (*), p < 0.01 (**) and p < 0.001 (***) as indicated, calculated using a t-test.
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STAT3 signalling. Taken together with our data showing 
CYLD defective tumours are sensitive to γ-secretase 
inhibitors, an oncogenic dependency on Notch is likely in 
this model. Our data highlights a novel interacting partner 
of CYLD, MIB2, that influences Notch signalling and 
furthermore the potential therapeutic utility of γ-secretase 
inhibition in CYLD defective tumours.
MATERIALS AND METHODS
Co-purification  of  CYLD-protein  complexes 
and MS identification
HEK-293T cells (5 × 10 cm dishes, seeded at 
2 ×106 cells) were transfected with pEBG-Empty and 
pEBG-CYLDUSP (amino acids 583-956). After 24 hours, 
the cells were split 1:2. After 48 hours the appropriate 
cells were treated with TNFα (50 ng/mL) for six hours. 
The cells were then chilled on ice, washed with cold 
PBS and lysed in cold lysis buffer for 30 minutes on ice 
(lysis buffer: 50 mM Tris pH 8, 150 mM NaCl, 1% Triton 
X-100, 10% glycerol, 1 mM EDTA, 1 mM DTT, 2 mM 
Benzamidine, 0.5 mM PMSF, protease inhibitor cocktail 
(Roche), 50 mM NaF, 1mM Na
3
VO
4
, 15 mM Na
4
P
2
O
7
). 
The lysates were then centrifuged and quantified 
(Bradford assay, Bio-Rad protein assay reagent). 
Glutathione sepharose (100 μL) was washed three times 
with lysis buffer before adding 5 mg of total lysate, with 
the final volume made up to 500 μL with lysis buffer. 
The mixtures were then incubated for 2 hours at 4oC on a 
turn disc. The resin was then collected by centrifugation, 
washed four times with wash buffer A (50 mM Tris pH 8, 
150 mM NaCl, 0.1% Triton X-100, 10% glycerol, 1 mM 
EDTA, 1 mM DTT, protease inhibitor cocktail (Roche), 
50 mM NaF, 1mM Na
3
VO
4
, 15 mM Na
4
P
2
O
7
) and twice 
with wash buffer B (50 mM Tris pH 8, 500 mM NaCl, 
0.1% Triton X-100, 10% glycerol, 1 mM EDTA, 1 mM 
DTT). The resin was then incubated with 300 μL elution 
buffer (50 mM Tris pH 8, 500 mM NaCl, 20 mM reduced 
glutathione, 1 mM EDTA) for 20 minutes. The supernatant 
Figure 7: A schematic representation of Notch signalling and the suggested role of CYLD. Notch signalling between 2 cells 
that is mediated by JAG2-NOTCH interaction. The CYLD-MIB2 complex negatively regulates JAG2 expression levels, resulting in a 
reduction of Notch activation. CYLD knockdown or truncation results in increased JAG2 expression Notch target gene activation (such as 
RUNX1) in adjacent cells.
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was then collected, 45 μL of 100% trichloroacetic acid 
was added and the sample mixed by vortex, followed by 
incubation at 4oC for 18 hours. The pellet was collected 
by centrifugation, washed with cold acetone, dried by 
speedi-vac and resuspended in SDS sample loading 
buffer. Residual TCA was neutralised by the addition 
of 1M Tris pH 10. The samples were then loaded onto a 
4–12% NuPAGE Bis-Tris gradient gel (Invitrogen) and 
run at 200 V for 1 hour. Protein bands were visualised 
by silver stain (SilverQuest™, Invitrogen) and bands of 
interest excised and identified by in-gel tryptic digest, 
Matrix Assisted Laser Desorption-TOF-TOF (TopLab 
GmbH, www.toplab.de, Proteomics analyser 4700) and 
peptide mass fingerprint (database search: GPS-Explorer/
Mascot). MIB2/skeletrophin was the top ranked ID with 
13% minimum sequence coverage.
Endogenous co-immunoprecipitation assay
293T cells (2x T175 flasks) were incubated with 
MG-132 (5 uM) for six hours without TNF-alpha. The 
cells were then washed with cold PBS and lysed in a 
total of 5 mL Lysis buffer (50 mM Tris pH 8, 250 mM 
NaCl, 0.5% NP-40, 2 mM DTT, 0.5 uM MG-132). The 
lysate was pre-cleared with Protein A/G sepharose (Santa 
Cruz) for 1 hour at 4oC on a turn disc, the sepharose was 
discarded and the lysate quantified and divided into two 
mixtures, A & B (8 mg total protein each). Some lysate 
was retained for whole cell lysate western blot control. 
To mixture A was added Rat anti-CYLD antibody (5 ug), 
to mixture B was added normal Rat IgG (5 ug) followed 
by incubation at 4oC overnight on a turn disc. Protein 
A/G sepharose (50 uL bed volume) was washed in lysis 
buffer and then added to the lysate-antibody mixtures. 
After incubation for 4 hours at 4oC on a turn disc, the resin 
was collected and washed copiously with lysis buffer. 
PAGE sample loading buffer was then added to the resin, 
the samples boiled and loaded onto 4–12% Bis-Tris gel 
alongside whole cell lysate control (100 ug). The electro-
blotted membrane was then probed with anti-MIB2 
antibody (1:500).
Tumour samples
Tumour tissue was obtained from patients 
undergoing surgery indicated to control tumour burden or 
for symptomatic relief, under regional ethical committee 
approval (REC REF:06/1001/59).
Plasmids, cell lines and reagents
Full length, untagged CYLD was sub-cloned into 
pcDNA-3.1 from FLAG-CYLD [9]. CYLD-C601A was 
obtained by site directed mutagenesis (Stratagene) of 
pcDNA-CYLD (1801-TGT>GCT) GST-CYLDUSP was 
obtained by PCR amplification of the CYLD USP domain 
and cloning into the pEBG vector. HA-MIB2 was a kind 
gift from Tamotsu Takeuchi, Kochi, Japan. HA-MIB2-
ΔRING was obtained by site directed mutagenesis of 
HA-MIB2 via creation of a STOP codon at residue 2829 
(TGC>TGA). pCW7-[Ubiquitin-His
6
] was obtained 
from R. Kopito, Stanford (via the ATCC/LGC Standards, 
MBA-85). Fugene 6 was purchased from Promega. 
HEK293T Notch reporter cells were obtained via 
use of Cignal RBP-Jk Reporter (luc) Kit: CCS-014L 
(SABiosciences, UK.). All cell lines were incubated at 
37oC and 5% CO
2
 in Dulbecco’s Modified Eagle Medium 
(GIBCO) with 10% Fetal Bovine Serum (GIBCO). All 
cell lines were monitored for mycoplasma infection. Anti-
HA antibody (Roche), anti-JAG2 antibody (New England 
Biolabs), anti-MIB2 antibody (Cambridge Bioscience 
Ltd) were used as per the manufacturers instructions. 
Monoclonal Rat anti-CYLD antibody was raised against 
the USP domain of recombinant CYLD protein and probed 
at 1;500 in 5% non-fat milk. HRP-conjugated secondary 
antibodies (Pierce) were used at 1:5000 in 5% non-fat 
milk. MG-132 and recombinant TNFα was obtained from 
Sigma Aldrich. Duplex siRNA pools (siGenome) targeting 
CYLD were obtained from OpenBiosystems. Nickel 
Sepharose 6 was obtained from GE Healthcare.
Ubiquitylation assays
HEK293T cells were transfected (Fugene 6) 
in 10cm dishes with 6ug total DNA of the indicated 
constructs at 1:2:3 ratio (CYLD 1μg, Ubiquitin-His
6
 2μg, 
MIB2/MIB2-ΔRING 3μg or pcDNA-Empty 3μg). After 
16 hrs cells were split into a 15cm dish and incubated 
overnight. Cells were then lysed in 3 mL denaturing 
buffer (8M Urea, 100 mM Tris pH 8, 40 mM imidazole, 
500 mM NaCl, 1mM DTT, 2% NP-40/IGEPAL, 10% 
(v/v) ethylene glycol), sonicated and centrifuged at 
maximum speed for 15 minutes. His-tagged ubiquitin 
conjugates were then isolated using nickel-sepharose 6 
resin (100 μL slurry). Lysates were incubated with the 
nickel-sepharose for 3 hrs by end over end rotation at 
4oC, copiously washed (3 × 1mL lysis buffer as above 
and then 3 × 1mL of a solution containing 50mM Tris, 
500mM NaCl, 40 mM imidazole, 1% (v/v) ethylene 
glycol). Samples were then eluted with 200 μL of 
buffer containing 300 mM imidazole, 50 mM Tris pH 
8, 500 mM NaCl, 10% (v/v) ethylene glycol. 1 mM 
EDTA and 1mM DTT was added to the eluates which 
were then quantified by Bradford assay. Samples were 
loaded (100 μg each) onto a 7% SDS-PAGE gel. After 
electro-blotting onto nitrocellulose, the membrane was 
probed with the indicated antibodies.
Notch assays
HEK-293T cells were transduced with a Cignal RBP-
Jk Reporter (luc) Kit: CCS-014L (SABiosciences, UK.). 
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After puromycin selection, pooled stable reporter cells 
were transfected with siRNA pools targeting CYLD 
(OpenBiosystems). Negative controls (non-targeting 
siRNA, siCON) were included. Transfected cells were 
then split after 12 hrs and re-seeded at sub-confluent 
levels. After 48 hrs the Notch (NICD) induced luciferase 
signal was quantified (One-Glo, Promega) and the results 
were normalized to cell viability (Cell-Titer Glo, Promega) 
in replicate wells and then to the siCON signal.
Immunohistochemistry
Tissue sections from the TMA were dewaxed 
with xylene and rehydrated in graded ethanols, before 
undergoing microwave antigen retrieval in sodium citrate 
buffer (pH 6.0). Tissue sections were then blocked with 
peroxidase blocking agent (DAKO) and then incubated 
with the HES1, RUNX1 and LEF1 primary antibodies 
(Cell Signalling). Tissue sections were then washed in 
phosphate buffered saline and probed with secondary 
HRP-conjugated antibodies, and staining was visualized 
with 3, 3’-Diaminobenzidine (DAB). Haematoxylin was 
used as a nuclear counterstain.
Microarray profiling
Genome-wide transcriptomic profiles of 32 CYLD 
defective tumours were generated, using RNA extracted 
from fresh frozen microdissected tissue as previously 
described [41]. In brief, a bead microarray platform 
was used to obtain the gene expression values from 
32 tumour samples and 10 perilesional controls. Control 
tissue consisted of epidermis, hair follicles and associated 
appendageal structures. This platform, Illumina WG-
DASL (San Diego, USA;http://www.illumina.com), 
allowed for monitoring of gene expression of 24, 526 
transcripts. 50ng of total RNA from each sample was 
converted to cDNA as per the supplied protocol and then 
hybridised to Illumina Human 8v3 chips. A confocal 
Illumina Infinium bead reader then scanned the chips and 
the signal values were extracted using Illumina Beadstudio 
software 3.0. The transcriptomes are accessible at 
www.ebi.ac.uk at accession number E-MTAB-352.
Quantitative PCR
Total RNA was extracted from cylindroma 
tumours as described previously [41], subject to DNAse 
digestion and then reverse transcribed using a Superscript 
III kit (Invitrogen, UK) according to manufacturers 
instructions. cDNA was then used for quantitative PCR 
with the following Taqman real time PCR primers HEY 1 
(Hs01114113_m1) , Beta –Actin - ACTB (Hs99999903_
m1) with a Taq polymerase master mix (ABI, UK) , in 
an ABI 7900HT thermal cycler. Gene expression was 
normalised to ACTB and comparisons in expression were 
made using the 2-ΔΔCt formula as the PCR reactions had 
similar efficiencies of amplification.
Protein expression quantification
5 representative immunohistochemistry images 
were taken from each tumour sample and control areas 
using a Zeiss Axioimager (Zeiss, UK). Image J software 
(v 1.48g –http://imagej.nih.gov/ij)) was used to quantify 
DAB staining. RGB values that were restricted to the 
colour of DAB in our staining protocol were used to 
select for areas in images that were DAB positive. 
The area of the image positive was then quantified and 
compared to the total area assessed to generate a ratio 
of positive staining. The mean of the ratios was used to 
generate a ratio per sample. The values in the tumours 
were then compared with the values in the controls using 
a t-test.
Primary culture of CYLD defective tumour 
explants, HaCAT cells and drug experiments
Primary culture of cells derived from fresh tumour 
tissue was carried out as previously described on 3D tissue 
culture scaffolds [30]. After 28 days in culture, these 
scaffolds were grown for a further 12 days in the following 
γ-secretase inhibitors (Tocris Bioscience, UK) or control. 
HaCats were grown on tissue culture scaffolds and then 
cultured in identical conditions for 12 days. YO-0107 and 
Ly 450139 (Semagacestat) were both diluted in DMSO 
and the final concentration of DMSO in these and in the 
drug free controls was 1%.
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